The Bristol-Myers Squibb Company’s checkpoint antibody Opdivo (nivolumab) hit a roadblock on 5 August when a Phase 3 study failed to meet its primary endpoint in patients with previously untreated non-small cell lung cancer. ---Subscribe to MedNous to access this article--- Company News Clinical Research
